Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: Pharmacokinetics with special consideration of free-drug concentration

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 2, 2007, Pages 277-284

  Burkhardt, Olaf ^a,b,c   Kumar, Vipul ^a   Katterwe, Denise ^c   Majcher Peszynska, Jolanta ^d   Drewelow, Bernd ^d   Derendorf, Hartmut ^a   Welte, Tobias ^b,c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

ICU patients; Protein binding; VAP

Indexed keywords

ALBUMIN; CREATININE; ERTAPENEM; METICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPOALBUMINEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; OPEN STUDY; PROSPECTIVE STUDY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VENTILATOR ASSOCIATED PNEUMONIA; VOLUNTEER; BLOOD; CRITICAL ILLNESS; METABOLIC CLEARANCE RATE; MIDDLE AGED; TREATMENT OUTCOME; URINE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33947501712     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl485     Document Type: Article

References (25)

1. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-903.
2. Craven DE, Kunches LM, Kilinsky V et al. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis 1986; 133: 792-6.
3. Rello J, Ollendorf DA, Oster G et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122: 2115-21.
4. Luna CM, Vujacich P, Niederman MS et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-85.
5. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22 387-94.
6. Ewig S, Torres A, El-Ebiary M et al. Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. Am J Respir Crit Care Med 1999; 159: 188-98.
7. American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
8. Wexler HM. In vitro activity of ertapenem: Review of recent studies. J Antimicrob Chemother 2004; 53 Suppl. 2: 11-21.
9. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52: 538-42.
10. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331-44.
11. Majumdar AK, Musson DG, Birk KL et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-11.
12. Musson DG, Majumdar A, Holland S et al. Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob Agents Chemother 2004; 48: 521-4.
13. Pletz MWR, Rau M, Bulitta J et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004; 48: 3765-72.
14. Burkhardt O, Majcher-Peszynska J, Borner K et al. Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery. J Clin Pharmacol 2005; 45: 659-65.
15. Power BM, Forbes AM, Van Heerden PV et al. Pharmacokinetics of drugs in critically ill patients. Clin Pharmacokinet 1998; 34 25-56.
16. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-34.
17. Burkhardt O, Brunner M, Schmidt S et al. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother 2006; 58: 632-8.
18. Mundkowski RG, Majcher-Peszynska J, Burkhardt O et al. A new simple HPLC assay for the quantification of ertapenem in human plasma, lung tissue, and bronchoalveolar lavage fluid. J Chromatogr B Analyt Technol Life Sci 2006; 832: 231-5.
19. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic models. In: D'Argenio DZ, ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic System Analysis. New York: Plenum Press, 1995; 69.
20. Wong BK, Bruhn PJ, Lin JH. Dose-dependent plasma clearance of MK-826, a carbapenem antibiotic, arising from concentration-dependent plasma protein binding in rats and monkeys. J Pharm Sci 1999; 88: 277-80.
21. Joynt GM, Lipman J, Gomersall CD et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001; 47: 421-9.
22. Pea F, Brollo L, Lugano M et al. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Ther Drug Monit 2001; 23: 587-8.
23. Liu P, Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin North Am 2003; 17: 599-613.
24. Craig WA. Pharmacodynamics of antimicrobials: General concepts and applications. In: Nightingale C, Marakawa T, Ambrose PG eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel-Dekker, 2002; 1-22.
25. Mouton JW, Touzw DJ, Horrevorts AM et al. Comparative pharmacokinetics of the carbapenems: Clinical implications. Clin Pharmacokinet 2000; 39: 185-201.